Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC — Stella

Home/Lung Cancer/Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC

View on ClinicalTrials.gov

Recruiting

Back to Lung Cancer trials

Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC

Trial locations(2 sites)

United States

The University of Kansas Cancer Center (KUCC), Fairway, Kansas

The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas

Key details

Sponsor

Jun Zhang, MD, PhD

Collaborators

Nilogen Oncosystems

Enrollment target

~25 participants

Started

July 2022

Primary completion

January 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 110 Years

Last updated February 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.